GTR Home > Tests > Signal PanCancer Panel

Overview

Test name

Help

Signal PanCancer Panel

Purpose of the test

Help

This is a clinical test intended for Help: Diagnosis, Monitoring, Predictive, Prognostic, Recurrence, Therapeutic management

Condition

Help

1 condition tested. Click Indication tab for more information.

How to order

Help

Streamlined workflow integration (EMR, Sema4 Provider Portal) for simplified ordering and easy access to results. Specimen accepted: For tumor: FFPE, Bone Marrow, Fresh Frozen, and Blood are accepted. For normal: Saliva, Buccal swab, and blood (if not involved in cancer). Tumor/normal pair required. 10 unstained slides of tumor, 10 microns each and H&E, paired normal (if tissue, similar; if blood then one tube (EDTA tube) of blood, or saliva or buccal swabs). To learn more about Sema4 WES/WTS, please visit https://sema4.com/products/test-catalog-old2020/signal-pancancer-panel/. Minimal samples accepted: FFPE: 9 unstained slides at 10 microns and 1 standard H&E; or 1 block. Fresh Frozen (5-10 mm3,). Bone Marrow: 3-5 ml EDTA. Blood: 3-5 ml EDTA. Saliva: 2.0 ml. Buccal swab: 1 swab. Tumor cellularity: >=20%. All specimens must be labeled with two unique identifiers. Slides should also be labeled with a block label identity that corresponds with the surgical pathology report. Must include a surgical pathology report where available.
Order URL Help: https://sema4.com/products/test-catalog-old2020/signal-pancancer-panel/

Specimen source

Bone marrow
Buccal swab
Cerebrospinal fluid
Fresh tissue
Frozen tissue
Isolated DNA
Paraffin block
Peripheral (whole) blood
Saliva

Methodology

Help
Molecular Genetics
DDeletion/duplication analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina NovaSeq 6000
  • None/not applicable
IMicrosatellite instability testing (MSI)
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina NovaSeq 6000
  • None/not applicable
RRNA analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina NovaSeq 6000
  • None/not applicable
ESequence analysis of select exons
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina NovaSeq 6000
  • None/not applicable
CSequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina NovaSeq 6000
  • None/not applicable
TTargeted variant analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina NovaSeq 6000
  • None/not applicable

Summary of what is tested

2196 genes and variants. Click Methodology tab for more information.

Genes

Clinical utility

Help

Not provided

Clinical validity

Help

Not provided

Test services

Help
  • Clinical Testing/Confirmation of Mutations Identified Previously
  • Confirmation of research findings
  • Data Storage and Backup
  • Tumor cellularity assessment by pathologist
  • Result interpretation
  • Specimen Source Identification

Clinical resources

Practice guidelines

  • ACMG, 2013
    American College of Medical Genetics and Genomics technical standards and guidelines: microarray analysis for chromosome abnormalities in neoplastic disorders.
  • AMP, 2012
    Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology.

Consumer resources

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Support Center